Remix Therapeutics
PrivateLast Round
Private Placement
Jun 24, 2026
Est. Valuation
$326M
Total Funding Raised
$183M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Remix Therapeutics is a biotechnology company that develops small molecule therapies designed to reprogram RNA processing to treat diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remix Therapeutics Comparables
Compare Remix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrakis Therapeutics | 86% | |
| Skyhawk Therapeutics | 80% | |
| Accent Therapeutics | 80% |
Remix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 24, 2026 | ||||
| VC Round | Jan 3, 2024 | ||||
| Series B | May 17, 2022 | ||||
| Series A | Dec 8, 2020 |
Key People
Founding team and executive leadership
Remix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A, Private Placement, Series B, Seed, VC Round |
| Surveyor Capital | VC Round, Series B |
| ARCH Venture Partners | Series A, VC Round, Series B |
| The Chernin Group | Series A, Series B, VC Round |
| ARCH Venture Partners | Series A, VC Round, Series B |
| Forge Life Science Partners | Private Placement |
| Foresite Capital | VC Round, Private Placement, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 24, 2026
$100M round led by Decheng Capital.
- May 17, 2026
Monthly visitors increased 37% MoM, reaching 4.5K.
Recent news
Latest coverage and updates
- hiresSep 9, 2026
Remix Therapeutics, Inc. hired Nicole Sweeny as Chief Commercial Officer on Sep 9th '26.
- attends_eventSep 1, 2026
Remix Therapeutics, Inc. attended event 21st Annual Wells Fargo Healthcare Conference on Jul 1st '26.
- receives_financingJun 25, 2026
remixtx.com received financing of $100M in private placement financing on Jun 25th '26.
- merges_withJun 25, 2026
remixtx.com merged with Passage Bio, Inc. on Jun 25th '26.
Remix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Remix Therapeutics's valuation, stock price, and market status.
Is Remix Therapeutics a public or private company?
Remix Therapeutics is a private company.
What is the current stock price of Remix Therapeutics?
Remix Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Remix Therapeutics worth (valuation)?
Valuation information for Remix Therapeutics is not publicly available.
Can I buy Remix Therapeutics stock?
Remix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Remix Therapeutics's last funding round?
Remix Therapeutics's most recent funding round was VC Round on January 3, 2024.
Who are the main investors in Remix Therapeutics?
Key investors in Remix Therapeutics include The Column Group, The Chernin Group, Foresite Capital, Citadel.
Will Remix Therapeutics IPO soon?
No public IPO plans have been announced for Remix Therapeutics.
How can I track Remix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Remix Therapeutics's secondary market activity and sign up for updates.